United Therapeutics Corporation - Common Stock (UTHR)
588.36
+65.53 (12.53%)
NASDAQ · Last Trade: Mar 30th, 10:09 PM EDT
Detailed Quote
Previous Close
522.83
Open
605.22
Bid
585.10
Ask
588.36
Day's Range
580.07 - 607.89
52 Week Range
266.98 - 607.89
Volume
1,722,230
Market Cap
26.41B
PE Ratio (TTM)
21.10
EPS (TTM)
27.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
663,685
Chart
About United Therapeutics Corporation - Common Stock (UTHR)
United Therapeutics is a biotechnology company focused on the development and commercialization of innovative therapies to treat chronic and life-threatening conditions, primarily in the fields of pulmonary hypertension and organ transplantation. Through its research efforts, the company aims to create and provide advanced medications that improve the quality of life for patients with severe health challenges. United Therapeutics is also engaged in initiatives to promote organ donation and transplantation, working towards enhancing the availability of organs for patients in need. Read More
What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 12.7% in the afternoon session after the company announced its TETON-...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint, demonstrating superiority over placebo for the change in absolute forced vital capacity (FVC) by 130.1 mL (Hodges-Lehmann [H-L] estimate, 95% confidence interval [CI], 82.2 to 178.1 mL; p <0.0001) from baseline to week 52.
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medicine has published full results of its phase 3 TETON-2 study evaluating the use of nebulized Tyvaso for the treatment of IPF. The publication is available online at NEJM.org.
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has authorized a new stock repurchase program of up to $2 billion over the next year. In addition, the company entered into ASR agreements with Citibank, N.A. (Citi) today to implement an initial $1.5 billion ASR program. The remaining amount of up to $500 million will be available for additional repurchases in United Therapeutics’ discretion, over a one-year period.
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide a company overview and update on Monday, March 9, 2026, from 1:00 to 1:30 p.m. EDT, at the Leerink Global Healthcare Conference in Miami Beach.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its long-term pivotal phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55% compared with placebo in patients with PAH (hazard ratio 0.45, 95% CI [0.33-0.62]; p<0.0001).
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR)
fell 7.2% in the afternoon session after the company reported fourth-quarter financial results that missed revenue expectations, overshadowing an earnings beat.
United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company cemented its status as a high-performance healthcare powerhouse by reporting a significant Q4 2025 earnings beat and officially surpassing the $3 billion annual revenue milestone for [...]
As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary arterial hypertension (PAH), the company has recently captured Wall Street’s attention with a series of high-stakes maneuvers. Following a stellar Q4 2025 earnings report released [...]
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 7.4% year on year to $790.2 million. Its GAAP profit of $7.70 per share was 14% above analysts’ consensus estimates.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024.
